Completed PHASE1 INTERVENTIONAL 4-arm NCT05187403

A Study of Laquinimod Eye-drops in Healthy Participants

A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye Drops

Sponsor: Active Biotech AB

Conditions Eye Diseases

Interventions Laquinimod Placebo

Updated 5 times since 2022 Last updated: Jan 30, 2023 Started: Dec 9, 2021 Primary completion: Jan 19, 2023 Completion: Jan 19, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Eye Diseases, this trial is completed. The trial is conducted by Active Biotech AB and has accumulated 5 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Active Biotech AB

Data source: Active Biotech AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria